Background:

The eosinophil major basic protein (EMBP), also designated MBP, PRG2, proteoglycan 2, BMPG, or bone marrow natural killer cell activator, is a constituent of the crystalline core of the eosinophil granule. High levels of the pro-EMBP are present in placenta and pregnancy serum, where it exists as a complex with several other proteins including pregnancy-associated plasma protein A (PAPPA), angiotensinogen (AGT) and C3δγ. EMBP may influence antiparasitic defense mechanisms as a cytotoxin and helminthotoxin, and may play a role in immune hypersensitivity reactions. EMBP stimulates an Src kinase-dependent activation of class I (A) phosphoinositide 3-kinase and, in turn, activation of protein kinase C ζ in neutrophils. EMBP transcription is under regulation by novel combinatorial interactions of GATA-1, PU.1, and C/EBPε isoforms.

Specificity:

Recognizes endogenous levels of PRG2 protein.

Alternative names:

MBP; Bone marrow proteoglycan; BMPG; Proteoglycan 2

Species reactivity:

Human, Mouse

Host:

Rabbit

Ig type:

Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide.

Immunogen:

Recombinant full length protein of human PRG2

Purification & Purity:

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).

Molecular weight:

~ 25 kDa

Applications:

WB, IHC

Usage:

WB (1/500 - 1/2000), IHC (1/50 - 1/200)

Storage:

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Precautions:

For research use only, not for use in diagnostic procedure.

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com